Does Highmark Cover Eliquis? A Complete 2025 Coverage Guide

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that works by selectively inhibiting coagulation Factor Xa. The FDA approved it in 2012 for reducing stroke and systemic embolism risk in nonvalvular atrial fibrillation, and later for deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment and prevention 1.

Coverage questions matter enormously because Eliquis has been one of the most prescribed anticoagulants in the United States. Approximately 6 million Americans live with atrial fibrillation, and guidelines from the American Heart Association recommend DOACs as the first-line agents for most of them 2. Paying full retail price, which can exceed $550 per 30-day supply, is simply not viable for most patients without insurance support.

Why Highmark's Formulary Decisions Are Complex

Highmark operates multiple distinct plan lines: commercial PPO and HMO products, employer self-funded plans, individual and family plans on the ACA marketplace, and Medicare Advantage (MA) plus Part D stand-alone plans. Each product line maintains its own formulary. A drug's tier on one plan does not automatically translate to the same tier on another, even within the same insurer.

Formulary decisions are reviewed annually. Highmark, like other Blue Cross Blue Shield licensees, negotiates rebates with manufacturers. Because generic apixaban entered the market in late 2023, formulary committees are actively reassessing where brand Eliquis sits relative to the new generic, which affects your 2025 cost-sharing.

What the Clinical Evidence Shows About Eliquis

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to warfarin in patients with atrial fibrillation. Apixaban reduced the primary endpoint of stroke or systemic embolism by 21% (hazard ratio 0.79; 95% CI 0.66 to 0.95; P<0.001 for non-inferiority, P=0.01 for superiority) and cut major bleeding by 31% compared with warfarin 3.

The AMPLIFY trial (N=5,395) studied apixaban versus enoxaparin/warfarin for acute VTE treatment. Apixaban was non-inferior for the primary efficacy outcome and caused significantly less major bleeding (0.6% vs. 1.8%; relative risk 0.31; 95% CI 0.17 to 0.55) 4.

These results underpin guideline support and explain why prescribers strongly prefer apixaban over warfarin for many patients.

How Highmark Structures Its Drug Formularies

Tier System Overview

Highmark uses a standard multi-tier formulary structure for most plans:

• Tier 1: Preferred generics (lowest copay, often $0, $15)
• Tier 2: Non-preferred generics and some lower-cost brands (moderate copay)
• Tier 3: Preferred brand-name drugs (higher copay, typically $40, $80 on commercial plans)
• Tier 4: Non-preferred brands (highest copay on non-specialty tier, often $80, $120+)
• Tier 5 / Specialty: High-cost biologics and specialty drugs

Brand Eliquis most commonly falls on Tier 3 or Tier 4 across Highmark commercial products. Generic apixaban, where it appears on Highmark formularies, typically lands on Tier 1 or Tier 2, representing significant savings.

Prior Authorization Requirements

Prior authorization (PA) means your physician must submit clinical justification before Highmark will approve the prescription at the in-network benefit level. Highmark applies PA to Eliquis on a significant share of its plans. Common PA criteria include:

1. Confirmed diagnosis of nonvalvular atrial fibrillation, DVT, PE, or post-orthopedic surgery prophylaxis
2. Documented CHA2DS2-VASc score of 2 or higher for atrial fibrillation patients (in line with AHA/ACC guidance) 2
3. Documentation that the prescribing provider has evaluated bleeding risk using a validated tool such as the HAS-BLED score 5

If PA is denied, your physician can submit a peer-to-peer review request or file a formal appeal within Highmark's appeals process.

Step Therapy Policies

Some Highmark plans impose step therapy, requiring patients to try a specified alternative first. Warfarin (generic, extremely low cost) and rivaroxaban (Xarelto) are the two most common step-therapy predecessors for Eliquis on plans that use this requirement.

The American College of Cardiology has raised concerns about step-therapy policies for anticoagulants, noting that forcing transitions between agents carries its own safety risk and monitoring burden 6. Thirty-five U.S. States have enacted step-therapy override laws that require insurers to grant exceptions when a prescriber documents that the required alternative is clinically inappropriate for a specific patient. Pennsylvania, where Highmark is headquartered, has a step-therapy protection law, and West Virginia and Delaware (other Highmark service areas) have enacted similar protections.

Eliquis on Highmark Medicare Advantage and Part D Plans

Medicare Advantage Formulary Placement

Highmark's Medicare Advantage plans are required to cover Eliquis if it appears on their formulary, which CMS reviews annually. Under CMS's 2024 and 2025 prescription drug plan guidelines, plans must cover at least two drugs in each therapeutic class 7.

Eliquis is on virtually all Highmark Medicare Advantage formularies, though its tier placement varies. Many MA plans place brand Eliquis on Tier 3 (preferred brand) while listing generic apixaban on Tier 1.

The Medicare Part D Coverage Gap

Before the Inflation Reduction Act, the "donut hole" created a sharp increase in out-of-pocket costs for beneficiaries who reached the coverage gap. Starting January 1, 2025, the IRA caps Medicare Part D out-of-pocket spending at $2,000 per year for all enrollees 8. This is a meaningful change for patients on chronic high-cost medications like Eliquis.

After a beneficiary hits the $2,000 annual cap, Highmark Part D covers 100% of the cost for the rest of the plan year. For patients who currently spend well above that threshold on Eliquis alone, this provision delivers real relief.

Low-Income Subsidy (Extra Help)

Beneficiaries who qualify for Medicare's Extra Help program (also called the Low-Income Subsidy) pay substantially reduced cost-sharing for all Part D drugs including Eliquis. The Social Security Administration reports approximately 13 million beneficiaries are eligible for Extra Help, though not all are enrolled 9. Patients who believe they qualify should apply through the SSA or contact their local State Health Insurance Assistance Program (SHIP) office.

What You Will Actually Pay: Cost Estimates by Plan Type

Exact cost-sharing depends on your specific plan's Summary of Benefits and Evidence of Coverage document. The figures below reflect common ranges and should be verified against your current plan documents.

Commercial Plans

On Highmark commercial plans with Eliquis on Tier 3, a 30-day supply typically costs $45, $80 after the deductible is met. Before the deductible is met, you may pay the full negotiated rate, which is often $200, $350 depending on the plan's contracted price. The Bristol-Myers Squibb / Pfizer Eliquis copay card can reduce commercial out-of-pocket costs to as low as $10 per month for eligible patients 10. Patients enrolled in government programs such as Medicare or Medicaid are not eligible for the manufacturer copay card.

Medicare Advantage Plans

Under Medicare Advantage, cost-sharing for Tier 3 drugs at a preferred pharmacy commonly runs $42, $100 per 30-day fill during the initial coverage phase. Mail-order (90-day supply) often carries a 2.5x multiplier rather than 3x, offering modest savings. After the 2025 IRA cap of $2,000 is reached, no further cost-sharing applies.

Employer Self-Funded Plans

Employers that self-fund their health benefits through Highmark as a third-party administrator set their own formulary tiers and cost-sharing. These plans may mirror the commercial Highmark formulary or use a custom formulary negotiated through a pharmacy benefit manager (PBM). Check your plan's Summary Plan Description (SPD) for exact tiers.

Generic Apixaban: The Formulary Shift Happening Right Now

Generic apixaban received FDA approval and launched commercially in the United States in late 2023 following the expiration of key Eliquis patents. Multiple manufacturers now produce generic versions 11.

The clinical bioequivalence data FDA reviewed confirms that approved generics deliver the same active ingredient at the same dose with comparable pharmacokinetics. The FDA standard requires a 90% confidence interval for peak plasma concentration (Cmax) and area under the curve (AUC) that falls within 80 to 125% of the reference product 12.

The HealthRX DOAC Formulary Decision Framework helps clinicians and patients identify the lowest-cost equivalent therapy while preserving clinical appropriateness. For Highmark members specifically, the decision path runs as follows:

1. Confirm diagnosis and indication (AF, DVT/PE treatment, DVT/PE prophylaxis, post-surgical prophylaxis).
2. Check whether generic apixaban appears on your specific Highmark plan's formulary at Tier 1 or Tier 2.
3. If generic is available and no contraindication exists, ask the prescriber to write "generic apixaban, substitution permitted."
4. If brand Eliquis is medically necessary (prescriber documents a specific clinical reason), proceed to PA submission.
5. If PA is denied, evaluate whether a step-therapy override applies under Pennsylvania, West Virginia, or Delaware state law.
6. If no override applies and alternatives are clinically acceptable, evaluate rivaroxaban (Xarelto) or dabigatran (Pradaxa) formulary placement on your specific plan.

Highmark members on commercial plans who switch to generic apixaban from brand Eliquis will likely see Tier 1 or Tier 2 cost-sharing, which translates to $0, $20 per 30-day fill on many plans. That savings compounds over 12 months to $300, $800 or more.

Alternatives to Eliquis on the Highmark Formulary

When brand Eliquis is not covered or is prohibitively expensive, clinicians typically consider three alternatives.

Warfarin (Generic)

Warfarin is generic, costs under $10 per month at most pharmacies, and appears on Tier 1 of virtually every Highmark formulary. The tradeoff is routine INR monitoring (typically monthly or more frequent), numerous drug and food interactions, and a narrower therapeutic index. The AHA/ACC guidelines note that DOACs are preferred over warfarin for most patients with nonvalvular AF who can tolerate them 2.

Rivaroxaban (Xarelto)

Rivaroxaban is another Factor Xa inhibitor with similar indications. Its formulary tier on Highmark plans can differ from Eliquis depending on current rebate contracts. The ROCKET AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for prevention of stroke in AF (HR 0.88; 95% CI 0.74 to 1.03; P<0.001 for non-inferiority) 13. Rivaroxaban is dosed once daily with the evening meal, versus apixaban's twice-daily dosing, which some patients find simpler.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor approved for stroke prevention in AF and VTE treatment. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily was superior to warfarin for stroke prevention (RR 0.66; 95% CI 0.53 to 0.82; P<0.001) 14. A specific antidote, idarucizumab (Praxbind), is available for emergency reversal.

Each alternative carries distinct pharmacokinetic and clinical profiles. Switching should only happen under physician supervision with a documented transition plan.

How to Appeal a Highmark Coverage Denial for Eliquis

Step 1: Request a Coverage Exception

Your prescribing physician submits a coverage exception request to Highmark explaining why Eliquis is medically necessary for you specifically. This often includes documentation of a contraindication to the required step-therapy drug, prior adverse events, or a clinical condition that makes the alternative inappropriate.

Step 2: File a Formal Appeal

If the exception is denied, you have the right to file a Level 1 Internal Appeal. Highmark is required to respond within 30 calendar days for standard appeals and 72 hours for expedited (urgent) appeals. Keep copies of all correspondence.

Step 3: External Review

If the internal appeal fails, you can request an External Independent Review through Pennsylvania's Insurance Department (or the relevant state authority for your plan). The independent reviewer's decision is binding on the insurer for fully insured plans.

Step 4: Use the Manufacturer Assistance Program While Appealing

The BMS/Pfizer Together Patient Assistance Program provides free Eliquis to eligible uninsured or underinsured patients who do not qualify for the copay card 10. Applying for this program does not delay or affect your insurance appeal.

Checking Your Specific Highmark Plan's Formulary

No article, including this one, can substitute for looking up your exact plan. Highmark posts all formularies online and updates them at least annually.

How to Check Online

1. Log in to your Highmark member portal at highmarkbcbs.com.
2. Manage to "Prescription Drugs" or "Drug Formulary."
3. Search for "apixaban" (the generic name) and "Eliquis" (the brand name) separately, because they may appear at different tiers.
4. Note the tier, any PA or step-therapy flags, and whether quantity limits apply.

How to Call

Call the member services number on the back of your Highmark ID card and ask specifically: (a) what tier is apixaban/Eliquis on my plan, (b) does my plan require prior authorization, and (c) does my plan require step therapy.

Document the representative's name, the date of the call, and the reference number. This documentation is useful if a claim is later disputed.

Ask Your Pharmacist

A licensed pharmacist can run a real-time eligibility check that shows your plan's copay before you fill the prescription. Most retail and mail-order pharmacies can do this in under two minutes.

The 2025 ACC/AHA Atrial Fibrillation Guideline states: "Shared decision-making between clinician and patient regarding anticoagulant choice should incorporate patient preferences, cost, tolerability, adherence, drug interactions, and kidney function." 2 Cost-sharing barriers are a recognized driver of non-adherence, and your care team should be part of the conversation about affordability.

Adherence Matters: The Clinical Risk of Skipping Doses

Anticoagulant non-adherence is not a minor inconvenience. Apixaban has a half-life of approximately 12 hours. Missing doses, particularly two or more consecutive doses, may allow Factor Xa activity to recover enough to increase clot risk 15.

A 2018 analysis published in the Journal of the American Heart Association found that patients with AF who had low anticoagulant adherence (proportion of days covered <80%) faced a significantly higher risk of ischemic stroke compared with patients with high adherence (HR 1.42; 95% CI 1.12 to 1.80) 16. Cost-related non-adherence is one of the most modifiable risk factors in this equation. Using every available coverage tool, from PA appeals to copay cards to generic substitution, directly affects patient safety.

Practical Next Steps for Highmark Members on Eliquis

Patients should take these concrete actions before their next prescription fill:

• Pull up the current Highmark formulary for your specific plan year and verify the tier for both brand Eliquis and generic apixaban.
• Ask your prescriber whether "generic apixaban" is clinically appropriate for your indication and, if so, to update the prescription.
• If brand-only is necessary, have your prescriber submit a PA request with the ARISTOTLE or AMPLIFY data and your specific clinical history as supporting documentation.
• Check eligibility for the BMS/Pfizer copay card at eliquis.com if you are on a commercial plan.
• If you are on Medicare, check whether you qualify for Extra Help through SSA.gov, and review how the 2025 $2,000 Part D cap applies to your plan year costs.

Your pharmacist can process a test claim for both generic apixaban and brand Eliquis at the same time to show the exact copay difference under your current benefit before you decide.